Amicus Swings to Profit on Strong Galafold, Pombiliti Sales

TL;DR

**FOLD is finally turning the corner with strong product sales driving a quarterly profit, making it a compelling buy for long-term growth in rare disease.**

AI Summary

Amicus Therapeutics, Inc. (FOLD) reported a significant turnaround in net income for the three months ended September 30, 2025, achieving a net income of $17.306 million compared to a net loss of $6.729 million in the prior-year period. This was driven by a robust 19.46% increase in net product sales, reaching $169.061 million from $141.517 million. For the nine months ended September 30, 2025, the company still posted a net loss of $28.800 million, a substantial improvement from the $70.845 million loss in the same period of 2024. Gross profit for the quarter rose to $149.594 million from $128.238 million, while operating expenses increased to $115.325 million from $106.579 million, primarily due to higher selling, general, and administrative expenses which climbed to $90.036 million from $75.106 million. The company's cash and cash equivalents decreased to $190.553 million as of September 30, 2025, from $213.752 million at December 31, 2024, but total assets grew to $868.811 million from $785.033 million. A key strategic move was the exclusive license agreement with Dimerix Bioscience Pty Limited on April 30, 2025, for DMX-200 in the U.S. for Focal Segmental Glomerulosclerosis (FSGS).

Why It Matters

This filing signals a positive shift for Amicus Therapeutics, demonstrating the commercial strength of its rare disease therapies, Galafold and Pombiliti + Opfolda. For investors, the swing to quarterly net income and improved nine-month loss indicates a clearer path to profitability and validates their investment in the company's product pipeline and commercialization efforts. Employees benefit from the company's growing revenue and strategic expansion, such as the Dimerix licensing deal, which suggests job stability and potential for future growth. Customers, particularly patients with Fabry and Pompe diseases, gain from the continued success and broader availability of these specialized treatments. In the competitive rare disease market, Amicus's performance underscores its ability to effectively commercialize niche therapies and potentially challenge larger pharmaceutical players.

Risk Assessment

Risk Level: medium — While Amicus reported a quarterly profit, the company still has an accumulated deficit of $2.8 billion as of September 30, 2025, and anticipates incurring losses through the fiscal year ending December 31, 2025. Cash and cash equivalents decreased by $23.199 million from December 31, 2024, to September 30, 2025, indicating ongoing cash burn despite improved operational performance.

Analyst Insight

Investors should consider initiating or increasing positions in FOLD, focusing on the positive trend in net product sales and the strategic Dimerix licensing agreement. Monitor the company's progress in reducing its accumulated deficit and achieving sustained profitability in subsequent quarters, as well as the commercialization trajectory of DMX-200.

Financial Highlights

debt To Equity

2.77

revenue

$169.061M

operating Margin

20.27%

total Assets

$868.811M

total Debt

$391.985M

net Income

$17.306M

eps

N/A

gross Margin

88.48%

cash Position

$190.553M

revenue Growth

+19.46%

Revenue Breakdown

Key Numbers

• $169.061M — Net product sales for Q3 2025 (Increased 19.46% from $141.517 million in Q3 2024)
• $17.306M — Net income for Q3 2025 (Swung from a net loss of $6.729 million in Q3 2024)
• $28.800M — Net loss for YTD Q3 2025 (Improved from a net loss of $70.845 million in YTD Q3 2024)
• $190.553M — Cash and cash equivalents as of Sep 30, 2025 (Decreased from $213.752 million at Dec 31, 2024)
• $868.811M — Total Assets as of Sep 30, 2025 (Increased from $785.033 million at Dec 31, 2024)
• $2.8B — Accumulated deficit as of Sep 30, 2025 (Indicates historical losses despite recent quarterly profit)
• 308,533,548 — Shares outstanding as of Oct 24, 2025 (Reflects total common stock outstanding)

Key Players & Entities

• AMICUS THERAPEUTICS, INC. (company) — Registrant
• Dimerix Bioscience Pty Limited (company) — Exclusive license agreement partner
• Galafold (company) — Marketed therapy for Fabry disease
• Pombiliti + Opfolda (company) — Marketed therapy for late-onset Pompe disease
• DMX-200 (company) — Phase 3 drug candidate for FSGS
• NASDAQ Global Market (regulator) — Exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• United States (regulator) — Country of DMX-200 commercialization rights

FAQ

Risk Factors

• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $2.769 billion as of September 30, 2025. While the company achieved net income in the third quarter of 2025, the nine-month period still shows a net loss, indicating a history of unprofitability that requires ongoing capital to sustain operations.
• Inventory Growth [medium — operational]: Inventories increased significantly from $118.782 million at December 31, 2024, to $177.928 million as of September 30, 2025. This substantial increase may indicate potential challenges in sales velocity or production planning, which could lead to write-downs or obsolescence if not managed effectively.
• Increased SG&A Expenses [medium — operational]: Selling, general, and administrative expenses rose to $90.036 million in Q3 2025 from $75.106 million in Q3 2024. This increase, contributing to higher total operating expenses, needs to be monitored to ensure it translates into commensurate revenue growth and market penetration.
• Drug Development and Approval Risks [high — regulatory]: As a biotechnology company, Amicus Therapeutics is subject to extensive regulatory scrutiny for drug development, clinical trials, and marketing approvals. Delays or failures in these processes, particularly for new candidates like DMX-200 for FSGS, can significantly impact future revenue streams and financial performance.
• Long-Term Debt [medium — financial]: The company carries $391.985 million in long-term debt as of September 30, 2025. While interest expense was managed in the quarter, significant debt obligations can strain cash flow, especially if revenue growth falters or interest rates rise.
• Competition in Rare Diseases [medium — market]: The rare disease market, where Amicus operates, is highly competitive. The success of its products depends on differentiation, efficacy, and market access against existing and emerging therapies. The exclusive license for DMX-200 highlights the strategic importance of pipeline expansion in this dynamic landscape.

Industry Context

Amicus Therapeutics operates in the highly specialized and competitive biotechnology sector, focusing on rare genetic diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Key trends include advancements in gene therapy, personalized medicine, and strategic partnerships to expand pipelines and market reach, as evidenced by Amicus's licensing agreement for DMX-200.

Regulatory Implications

As a biopharmaceutical company, Amicus faces significant regulatory hurdles. The approval process for new drugs is lengthy and costly, with potential for delays or outright rejection by agencies like the FDA. Compliance with manufacturing standards, post-market surveillance, and evolving healthcare policies are critical for sustained market access and revenue generation.

What Investors Should Do

1. Monitor SG&A expense growth relative to revenue.
2. Evaluate inventory levels and turnover.
3. Assess the progress and potential of the DMX-200 license.
4. Analyze the path to sustained profitability.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net income of $17.306 million, a significant turnaround from a net loss in the prior year, driven by increased product sales.
• 2025-04-30: Exclusive License Agreement with Dimerix Bioscience Pty Limited — Acquired rights to DMX-200 for FSGS in the U.S., potentially expanding the company's pipeline and future revenue opportunities in a key therapeutic area.
• 2025-09-30: Consolidated Balance Sheet Date — Showcased total assets of $868.811 million and cash and cash equivalents of $190.553 million, indicating growth in assets despite a decrease in cash from year-end 2024.
• 2025-09-30: Consolidated Statement of Operations Date — Reflected year-to-date net loss of $28.800 million, an improvement from $70.845 million in the prior year, demonstrating progress towards profitability.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (Indicates the company's long-term profitability history. Amicus has a significant accumulated deficit of $2.769 billion, highlighting its reliance on external funding to cover past losses.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. It represents the value of brand recognition, customer loyalty, etc. (Amicus has $197.797 million in goodwill, likely from past acquisitions, which is a significant portion of its non-current assets.)

Operating lease right-of-use assets, net

Represents the value of a company's right to use an asset over the lease term, recognized under accounting standards that require most leases to be recorded on the balance sheet. (Amicus has $21.549 million in these assets, reflecting its long-term rental commitments for property or equipment.)

Intangible assets, less accumulated amortization

Non-physical assets like patents, trademarks, or licenses that have a finite useful life and are gradually expensed over that life (amortized). (Amicus has $14.743 million in net intangible assets, which could include intellectual property related to its therapies.)

Common stock in treasury

Shares of a company's own stock that it has repurchased from the open market. These shares are not considered outstanding and do not have voting rights. (Amicus holds 7,390 shares in treasury as of September 30, 2025, which is a small portion of its total shares outstanding.)

Year-Over-Year Comparison

Compared to the prior year, Amicus Therapeutics demonstrates a significant positive shift in quarterly performance, with net product sales increasing by 19.46% to $169.061 million and a swing from a net loss to a net income of $17.306 million in Q3 2025. Year-to-date, the net loss has narrowed considerably from $70.845 million to $28.800 million. However, operating expenses, particularly SG&A, have risen, and cash reserves have decreased, while total assets have grown, indicating ongoing investment and expansion.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share FOLD NASDAQ Global Market

Filing Documents

• fold-20250930.htm (10-Q) — 1080KB
• a101.htm (EX-10.1) — 23KB
• a102.htm (EX-10.2) — 25KB
• fold-09302025xex311.htm (EX-31.1) — 11KB
• fold-09302025xex312.htm (EX-31.2) — 11KB
• fold-09302025xex321.htm (EX-32.1) — 8KB
• 0001178879-25-000015.txt ( ) — 5751KB
• fold-20250930.xsd (EX-101.SCH) — 31KB
• fold-20250930_cal.xml (EX-101.CAL) — 64KB
• fold-20250930_def.xml (EX-101.DEF) — 112KB
• fold-20250930_lab.xml (EX-101.LAB) — 515KB
• fold-20250930_pre.xml (EX-101.PRE) — 329KB
• fold-20250930_htm.xml (XML) — 832KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

Consolidated Financial Statements and Notes (unaudited)

Item 1. Consolidated Financial Statements and Notes (unaudited) 3 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Consolidated Statements of Operations for the Three and N ine Months Ended September 30, 2025 and 2024 4 Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024 5 Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 27

Controls and Procedures

Item 4. Controls and Procedures 27

OTHER INFORMATION

PART II. OTHER INFORMATION 27

Legal Proceedings

Item 1. Legal Proceedings 27

Risk Factors

Item 1A. Risk Factors 27

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 28

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 28

Other Information

Item 5. Other Information 29

Exhibits

Item 6. Exhibits 30

SIGNATURES

SIGNATURES 31 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions. Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "might," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: the scope, progress, results and costs of clinical trials for our drug candidates; the cost of manufacturing drug supply for our commercial, clinical and preclinical studies, including the cost of manufacturing Pombiliti (also referred to as "ATB200" or "cipaglucosidase alfa"); the future results of preclinical research and subsequent clinical trials for pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize such therapies; the costs, timing, and outcome of

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED)

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED) Amicus Therapeutics, Inc. Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 190,553 $ 213,752 Investments in marketable securities 73,290 36,194 Accounts receivable 113,838 101,099 Inventories 177,928 118,782 Prepaid expenses and other current assets 38,457 34,909 Total current assets 594,066 504,736 Operating lease right-of-use assets, net 21,549 22,278 Property and equipment, less accumulated depreciation of $ 31,271 and $ 28,775 at September 30, 2025 and December 31, 2024, respectively 27,759 29,383 Intangible assets, less accumulated amortization of $ 8,257 and $ 5,802 at September 30, 2025 and December 31, 2024, respectively 14,743 17,198 Goodwill 197,797 197,797 Other non-current assets 12,897 13,641 Total Assets $ 868,811 $ 785,033 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 19,103 $ 12,947 Accrued expenses and other current liabilities 171,165 127,300 Operating lease liabilities 8,662 8,455 Total current liabilities 198,930 148,702 Long-term debt 391,985 390,111 Operating lease liabilities 42,174 45,078 Other non-current liabilities 5,298 7,097 Total liabilities 638,387 590,988 Commitments and contingencies Stockholders' equity: Common stock, $ 0.01 par value, 500,000,000 shares authorized, 308,499,614 and 299,041,653 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 3,017 2,944 Common stock in treasury, at cost; 7,390 shares as of September 30, 2025 ( 71 ) — Additional paid-in capital 2,973,625 2,926,115 Accumulated other comprehensive income (loss): Foreign currency translation adjustment 22,886 5,302 Unrealized loss on available-for-sale securities ( 53 ) ( 207 ) Warrants — 71 Accumulated deficit ( 2,768,980 ) ( 2,740,180 ) Total stockholders' equity

View Full Filing

View this 10-Q filing on SEC EDGAR